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Abstract
Background: Trehalose is hydrolyzed by a specific intestinal brush-border disaccharidase (trehalase) into two
glucose molecules. In animal studies, trehalose has been shown to prevent adipocyte hypertrophy and mitigate
insulin resistance in mice fed a high-fat diet. Recently, we found that trehalose improved glucose tolerance in
human subjects. However, the underlying metabolic responses after trehalose ingestion in humans are not well
understood. Therefore, we examined the glycemic, insulinemic and incretin responses after trehalose ingestion in
healthy Japanese volunteers.
Methods: In a crossover study, 20 fasted healthy volunteers consumed 25 g trehalose or glucose in 100 mL water.
Blood samples were taken frequently over the following 3 h, and blood glucose, insulin, active gastric inhibitory
polypeptide (GIP) and active glucagon-like peptide-1 (GLP-1) levels were measured.
Results: Trehalose ingestion did not evoke rapid increases in blood glucose levels, and had a lower stimulatory
potency of insulin and active GIP secretion compared with glucose ingestion. Conversely, active GLP-1 showed
higher levels from 45 to 180 min after trehalose ingestion as compared with glucose ingestion. Specifically, active
GIP secretion, which induces fat accumulation, was markedly lower after trehalose ingestion.
Conclusions: Our findings indicate that trehalose may be a useful saccharide for good health because of properties
that do not stimulate rapid increases in blood glucose and excessive secretion of insulin and GIP promoting fat
accumulation.
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Background
Trehalose is a non-reducing disaccharide that consists of
two glucose units linked by a α, α-1,1-glucosidic bond.
Trehalose is widespread in nature such as plants, fungi
and insects, and helps to preserve the life of plants and
animals [1, 2]. Although trehalose was previously con-
sumed from natural sources, it has been manufactured
from starch through a proprietary enzymatic process
since 1995. As a result, trehalose is widely used in a var-
iety of foods to protect against dryness, freezing and os-
motic pressure stresses.
In previous studies, we showed that trehalose intake
prevented adipocyte hypertrophy and mitigated insulin
resistance in mice fed a high-fat diet [3, 4]. In addition,
it has been reported that trehalose has various biological
effects such as suppression of bone resorption [5] and
inflammatory response [6], induction of autophagy [7, 8]
and alleviation of Huntington’s disease [9]. Although
these effects were found in vitro or in vivo studies, there
was little information available about the physiological
functions of trehalose in humans.
Oku et al. have reported that trehalose is a carbohy-
drate that does not raise blood glucose levels quickly
and induces lower insulin secretion compared with glu-
cose in female students (age 21.8 ± 5.4) [10]; however,
data from a broad age-range of people, including men,
remain unknown. Furthermore, the incretin response re-
lated to glucose metabolism following trehalose intake* Correspondence: chiyo.yoshizane@hb.nagase.co.jp
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has not been examined in human subjects. Incretins are
gut hormones that are secreted from enteroendocrine
cells into the blood after eating and promote insulin se-
cretion [11]. Gastric inhibitory polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1) are main incretins in
humans. In recent years, incretin receptor has been de-
tected in many organs, and its various physiological
extrapancreatic effects have received a lot of attention
[12]. For example, it is known that GIP promotes bone
formation [13] and fat accumulation in adipose tissue
[14]. This incretin also has been reported to suppress
gastric acid secretion in the gastrointestinal tract [15]. In
addition, GLP-1 promotes cardioprotection in the heart
[16] and delay gastric emptying in the gastrointestinal
tract [17]. In this study, we examined glycemic, insuline-
mic and incretin responses after oral trehalose ingestion
in healthy human subjects.
Methods
Subjects
Twenty-four healthy Japanese subjects (13 women and
11 men; mean age = 37.8 ± 1.6 years, BMI = 20.7 ±
0.3 kg/m2) were recruited. All subjects were informed
about the purpose, methods, and possible risks of the
study before giving their consent to participate.
This study was approved by the Ethics Committee of
Hayashibara Co. Ltd. (approval No. 152) and the Nishi
Clinic Ethics Committee (approval No. R1301) (Osaka,
Japan). And this study was carried out in Oneness Sup-
port Co., Ltd., and the Miura Clinic (Osaka, Japan). All
studies were conducted in accordance with the Declar-
ation of Helsinki (adopted in 1964 and revised in 2008)
and Japan’s Ethical Guidelines for Epidemiology Re-
search (adopted in 2002 and revised in 2004).
Test substances
TREHA™ (Hayashibara Co. Ltd., Okayama, Japan) was
used as the source of trehalose. It contains more than
98.0% of trehalose dihydrate. Glucose“Yoshida” (Yoshida
Pharmaceutical Inc., Tokyo, Japan) consists of 100% glu-
cose anhydrous.
Study design
Subjects were studied following an overnight fast in the
morning on two occasions with an interval of at least
1 week. Trehalose and glucose were ingested during two
different trials using a cross-over design.
Although trehalose is hydrolyzed in the small intestine,
it was reported that some people caused high osmotic
diarrhea because trehalose was not digested completely
when large enough amounts were ingested at the same
time [10]. In this study, therefore, we decided the quan-
tity of load substance as 25 g, not 50 g generally used
for Glycemic Index determination.
Twenty-five grams of trehalose (i.e., 28 g of TREHA™)
or glucose were dissolved in 100 mL water and ingested
in a gross quantity within 2 min. Venous blood samples
were taken before and 15, 30, 45, 60, 90, 120 and
180 min after ingestion. All blood samples were divided
at each time point for use in measurements of plasma
glucose (Ultraviolet absorption spectrophotometer),
serum insulin (Chemiluminescent enzyme immuno-
assay), plasma active GIP and active GLP-1 (Solid-phase
extraction-enzyme-linked immunosorbent assay) by
SRL, Inc. (Nara, Japan).
Data analysis
Time to maximum plasma or serum concentrations
(Tmax) and the maximum plasma or serum concentra-
tions (Cmax) were directly obtained from the plasma or
serum concentration time-course data.
The area under the curve for blood glucose, insulin,
active GIP or active GLP-1 levels was calculated as the
incremental area under the response curve (IAUC), ig-
noring the area beneath the fasting concentration.
Statistics
Each outcome measure is expressed as the mean ± the
standard error (SE). Paired Student’s t-tests were applied
for the analysis of Tmax, Cmax and IAUC between tre-
halose and glucose ingestion. For plasma or serum time
curves, two–way repeated measures ANOVA (MAN-
OVA) analyze with ingestion, time, and their interaction
was used to identify differences between treatments over
time. When interaction or ingestion effects were ob-
served, Wilcoxon post hoc analysis was performed to lo-
cate these differences. A value of p < 0.05 was considered
to be statistically significant. All calculations were per-
formed with JMP 9 (SPS Institute Inc.).
Results
Analytical subjects of this study
Among 24 participants in this study, one subject was
shown to be anemic at blood sampling, two subjects ex-
perienced borborygmus and diarrhea after receiving the
investigational test substance, and one subject was sus-
pected to have insulin resistance because of high fasting
blood insulin levels. Diarrhea symptoms emerged at 50
and 90 min after ingestion of trehalose in the two sub-
jects, with the diarrhea present for several hours. A
medical review suggested the presence of osmotic diar-
rhea due to incompleted digestion in the small intestine
and hence the subjects were withdrawn. Therefore, we
surveyed the data of 20 subjects (ten women and ten
men; mean age = 39.0 ± 1.6 years: range = 23–48, BMI =
20.8 ± 0.3 kg/m2: range = 18.3–23.5) as the final analyt-
ical results in this study.
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Change of blood glucose and insulin levels
Postprandial venous blood glucose and insulin levels are
presented in Fig. 1. Trehalose ingestion significantly low-
ered blood glucose and insulin peaks compared with
glucose ingestion. Blood glucose and insulin levels ob-
served in trehalose loading were significantly lower than
those in glucose loading at 15, 30, 45 and 60 min after
ingestion. Conversely, blood glucose values at 120 and
180 min, and insulin values at 180 min after trehalose
ingestion were significantly higher than those after glu-
cose ingestion.
Table 1 showed the metabolic responses after ingestion
of trehalose or glucose. Tmax of blood glucose and insu-
lin did not differ between trehalose and glucose loading.
Cmax and IAUC(0-2 h) of blood glucose and insulin in
trehalose loading were significantly lower than those in
glucose loading.
Change of blood incretin levels
Postprandial venous blood active GIP and GLP-1 levels
were presented in Table 1 and Fig. 2.
Cmax of active GIP in trehalose loading was signifi-
cantly lower than that in glucose loading (Table 1). Fur-
thermore, active GIP levels observed in trehalose loading
were lower than those in glucose loading at 15, 30, 45,
60 and 90 min after ingestion (Fig. 2).
Cmax of active GLP-1 was not significantly different
between trehalose and glucose loading (Table 1). More-
over, active GLP-1 levels observed at 45, 60, 90, 120 and
180 min after trehalose ingestion were significantly
higher than those after glucose ingestion (Fig. 2).
Discussion
As a result of experiments in healthy human subjects,
both blood glucose and insulin levels were found to be
significantly lower following trehalose loading compared
with glucose loading. Furthermore, active GIP levels
were markedly lower following trehalose loading com-
pared with glucose loading. Sex differences were not
found in these responses (data not presented).
Diarrhea symptom was observed in the two subjects
when 25 g of trehalose were dissolved in 100 mL water
and administered in this study. Whereas sixty German
subjects were given a 50 g dose of trehalose, on the
other hand, diarrhea and malabsorption were not ob-
served in any of the subjects as reported by Bolte et al.
[18]. In their study, 400 mL of water was used to admin-
ister 50 g of trehalose. In case of Oku et al. [10], further-
more, several dosages of trehalose dissolved in 100–
150 mL of tap water were given and no subjects had
diarrhea when administered at least 30 g of trehalose.
Fig. 1 Time-course of blood glucose and insulin levels following ingestion of 25 g of trehalose or glucose. Twenty fasted healthy participants
consumed 25 g of trehalose or glucose and changes in concentrations of plasma glucose and serum insulin were measured frequently. Data are
expressed as means ± SE (n = 20). Data were analyzed with a 2-factor repeated-measures (Ingestion × Tine) ANOVA. ** Significant difference from
trehalose and glucose: **p < 0.01 (Wilcoxon post hoc analysis)
Table 1 Indexes of the metabolic response after ingestion of
25 g of trehalose or glucose
Fasting values Cmax Tmax IAUC (0–2 h)
Blood Glucose mg/dL mg/dL min mg/dL 2 h
Glucose 88 ± 1 154 ± 4 39 ± 2 3185 ± 277
Trehalose 87 ± 1 111 ± 4 ** 50 ± 6 1201 ± 202 **
Insulin μIU/mL μIU/mL min μIU/mL 2 h
Glucose 3.77 ± 0.34 38.1 ± 3.2 36 ± 2 1709 ± 142
Trehalose 4.25 ± 0.50 15.5 ± 2.5 ** 39 ± 4 590 ± 101 **
Active GIP pmol/L pmol/L min pmol/L 2 h
Glucose 4.2 ± 0.6 49.9 ± 5.8 19 ± 2 2020 ± 212
Trehalose 4.7 ± 1.6 12.6 ± 2.4** 47 ± 10 * 260 ± 50 **
Active GLP-1 pmol/L pmol/L min pmol/L 2 h
Glucose 1.7 ± 0.1 4.9 ± 0.8 23 ± 2 93 ± 19
Trehalose 2.0 ± 0.2 * 4.6 ± 0.4 32 ± 3 * 116 ± 19
GIP gastric inhibitory polypeptide, GLP-1 glucagon-like peptide-1
Data are expressed as means ± SE (n = 20). Differences between glucose and
trehalose were assessed using a paired Student’s t-test. Significantly different
from glucose, *p < 0.05, **p < 0.01
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Together with these results, it is possible that diarrhea
symptom is caused by the concentration of trehalose so-
lution when given to subject but not total quantity.
Individual blood glucose IAUC after trehalose inges-
tion was lower than after glucose ingestion. Although a
blood glucose IAUC ratio of trehalose loading to glucose
loading was individually different, the mean of these
values for all subjects was 38% in the present study. This
value is equivalent to the glycemic index, which was in-
troduced to classify carbohydrate foods according to the
degree of postprandial glycemia. In general, low glycemic
index foods improve blood glucose control, the blood
lipid profile and fibrinolytic activity in diabetic subjects
[19, 20]. Furthermore, postprandial spikes in blood glu-
cose can cause damage to fragile blood vessels in the
heart, brain, kidneys, eyes and feet [21–23]. Trehalose
might help prevent these risks because it did not rapidly
raise blood glucose levels after ingestion, but requires
evealuation for potential usefulness as a sweetener for
diabetic patients.
Moreover, the mean individual blood insulin IAUC ra-
tio of trehalose loading to glucose loading was 36%.
Hyperinsulinemia characterizes impaired glucose toler-
ance and obesity, and reflects peripheral insulin resist-
ance [24]. Therefore, food materials that do not cause a
rapid rise in blood glucose levels and excessive insulin
secretion have been expected to prevent onset and pro-
gression of lifestyle-related diseases.
Interestingly, active GIP secretion following trehalose
loading was conspicuously lower than that of glucose
loading. The mean individual blood GIP IAUC ratio of
trehalose loading to glucose loading was only 14%. GIP
is secreted from K cells, which exist in the upper small
intestine, by the stimulation of nutrients such as carbo-
hydrates and lipids [14]. It is thought that ingested tre-
halose provides little stimulation to K cells during the
process of digestion and absorption in the gastrointes-
tinal tract. The lower active GIP concentration found in
this study might be one of the mechanisms behind lower
insulin release following trehalose ingestion. Recently, a
relationship between GIP and obesity has been clarified,
and it has been understood that GIP has a physiological
role in the nutrient uptake into adipose tissues, thereby
linking over nutrition to obesity [14, 25]. Furthermore, it
has been reported that GIP receptor-deficient mice fed a
high-fat diet were protected from obesity [25]. Restrain-
ing GIP signals may lead to the reduction of disease risk
such as obesity. In previous reports, we showed that the
intake of trehalose suppressed adipocyte hypertrophy
and mitigated insulin resistance in mice fed a high-fat
diet [3, 4]. Additionally, we confirmed that the con-
sumption of trehalose with a meal three times daily im-
proved glucose tolerance and mitigated the progression
of insulin resistance in humans [26]. Low secretion char-
acteristics of GIP may contribute to the suppression of
adipocyte hypertrophy and insulin resistance.
In contrast, it is known that GLP-1 protects pancreatic
β-cells and suppresses appetite. In this study, although
the active GLP-1 levels following trehalose loading were
higher than those following glucose loading from 45 to
180 min after ingestion, the levels were very low prob-
ably because of rapid disintegration from the enzyme
dipeptidyl peptidase-4 (DPP-4). Therefore, we could not
argue that trehalose loading led to higher levels of active
GLP-1 secretion than glucose loading in this study. A
further study is planned in our laboratory.
Recently, DeBosch et al. [8, 27] proposed a model that
trehalose inhibits multiple glucose transporter (GLUT)
family members through docking in the inward open
conformation of glucose transporters. Therefore, trehal-
ose may prevent excessive glucose absorption in the
small intestine by inhibiting glucose transporter
Fig. 2 Time-course of blood incretin levels following ingestion of 25 g of trehalose or glucose. Twenty fasted healthy participants consumed 25 g
of trehalose or glucose and changes in concentrations of plasma active GIP and plasma active GLP-1 were measured frequently. Data are expressed as
means ± SE (n = 20). Data were analyzed with a 2-factor repeated-measures (Ingestion × Time) ANOVA. *,** Significant difference from trehalose and
glucose: *p < 0.05, **p < 0.01. (Wilcoxon post hoc analysis)
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function. Furthermore van Can et al. [28] reported the
implications for postprandial trehalose ingestion reduced
glycemic responses in impaired glucose-tolerant sub-
jects. Therefore a consuming trehalose with daily meals
may contribute to the maintenance of good health
through the prevention of hyperglycemia. Also trehalose
may possibly contribute with useful saccharide in predia-
betic and type 2 diabetic patients. These possibilities
must be resolved in the future.
In conclusion, we have shown that it is hard for trehal-
ose to give rise to hyperglycemia and hypersecretions of
insulin and GIP following ingestion. These results indi-
cate that trehalose may be a useful saccharide for good
health because of properties that do not stimulate rapid
increases in blood glucose and excessive secretion of in-
sulin and GIP promoting fat accumulation.
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